{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:12Z","timestamp":1783980192416,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.japh.2025.102348","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:13:49Z","timestamp":1739362429000},"page":"102348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacy harm reduction practices to help reduce opioid overdoses, Arizona 2023"],"prefix":"10.1016","volume":"65","author":[{"given":"Beth E.","family":"Meyerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan P.Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Vadiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias O.","family":"Higbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava A.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison","family":"Seckar-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylee","family":"Newgass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2025.102348_bib2","series-title":"Drug Overdose Deaths in the United States, 2001\u20132021","first-page":"457","author":"Spencer","year":"2022"},{"issue":"6","key":"10.1016\/j.japh.2025.102348_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14925","article-title":"Estimated reductions in opioid overdose deaths with sustainment of public health interventions in 4 US states","volume":"6","author":"Chhatwal","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.japh.2025.102348_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamapsychiatry.2022.5159","article-title":"Twenty-year trends in drug overdose fatalities among older adults in the US","volume":"80","author":"Humphreys","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2025.102348_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2025.102348_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0376-8716(03)00169-8","article-title":"Buprenorphine versus methadone maintenance: a cost-effectiveness analysis","volume":"71","author":"Doran","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.japh.2025.102348_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a Cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.japh.2025.102348_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37259","article-title":"Projected estimates of opioid mortality after community-level interventions","volume":"4","author":"Linas","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.japh.2025.102348_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2025.102348_bib11","series-title":"Pharmacy-Based Methadone: Analysis of Current Laws and Regulations","author":"Woodruff","year":"2024"},{"key":"10.1016\/j.japh.2025.102348_bib12","article-title":"Dialing for doctors: secret shopper study of Arizona methadone and buprenorphine providers, 2022","volume":"160","author":"Meyerson","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"5","key":"10.1016\/j.japh.2025.102348_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.japh.2025.102348_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jrh.12404","article-title":"Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine","volume":"36","author":"Andrilla","year":"2020","journal-title":"J Rural Health"},{"issue":"3","key":"10.1016\/j.japh.2025.102348_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/add.14436","article-title":"Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder","volume":"114","author":"Jones","year":"2019","journal-title":"Addiction"},{"issue":"2S","key":"10.1016\/j.japh.2025.102348_bib17","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2025.102348_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103321","article-title":"Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City","volume":"97","author":"Marotta","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.japh.2025.102348_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2025.102348_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2025.102348_bib21","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"10.1016\/j.japh.2025.102348_bib22","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists' buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2025.102348_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2025.102348_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12954-022-00651-3","article-title":"Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic","volume":"19","author":"Dadiomov","year":"2022","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.japh.2025.102348_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.japh.2025.102348_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.21939","article-title":"Naloxone accessibility under the state standing order across Mississippi","volume":"6","author":"Gravlee","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.japh.2025.102348_bib31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.japh.2020.01.030","article-title":"Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies","volume":"60","author":"Spivey","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2025.102348_bib32","first-page":"13","article-title":"Considering the potential benefits of over-the-counter naloxone","volume":"10","author":"Evoy","year":"2021","journal-title":"Integr Pharm Res Pract"},{"key":"10.1016\/j.japh.2025.102348_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.15585\/mmwr.mm6935a1","article-title":"Vital signs: characteristics of drug overdose deaths involving opioids and Stimulants \u2014 24 states and the District of Columbia, January\u2013June 2019","volume":"69","author":"O'Donnell","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.japh.2025.102348_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1353\/hpu.2021.0107","article-title":"Insufficient access: naloxone availability to laypersons in Arizona and Indiana, 2018","volume":"32","author":"Meyerson","year":"2021","journal-title":"J Health Care Poor Underserved"},{"issue":"6","key":"10.1016\/j.japh.2025.102348_bib38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"49","key":"10.1016\/j.japh.2025.102348_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12954-024-00943-w","article-title":"Come back when you\u2019re infected: secret shopper study of pharmacy syringe sales in Arizona, USA 2023","volume":"21","author":"Russell","year":"2024","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.japh.2025.102348_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2018.03.032","article-title":"Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016","volume":"188","author":"Meyerson","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2025.102348_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drugpo.2018.02.024","article-title":"Predicting pharmacy syringe sales to people who inject drugs: policy practice and perceptions","volume":"56","author":"Meyerson","year":"2018","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2025.102348_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.sapharm.2016.09.007","article-title":"Using the hybrid method to survey U.S. pharmacists: applying lessons learned to leverage technology","volume":"13","author":"Agley","year":"2016","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.japh.2025.102348_bib43","series-title":"StatPearls [Internet]","article-title":"Buprenorphine","author":"Kumar","year":"2025"},{"issue":"2","key":"10.1016\/j.japh.2025.102348_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/00185787211024217","article-title":"Conscientious objection: a review of state pharmacy laws and regulations","volume":"57","author":"Achey","year":"2022","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.japh.2025.102348_bib46","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.japh.2025.102348_bib47","series-title":"PROC LCA & PROC LTA (Version 1.3.2) [Software]","year":"2015"},{"key":"10.1016\/j.japh.2025.102348_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study","volume":"211","author":"Joudrey","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.japh.2025.102348_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3174\/ajnr.A2425","article-title":"Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms","volume":"32","author":"Naggara","year":"2011","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:15:42Z","timestamp":1762550142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1544319125000275"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102348","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacy harm reduction practices to help reduce opioid overdoses, Arizona 2023","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102348"}}